Kolexia
Pouessel Damien Oncologie médicale
Pouessel Damien
Oncologie médicale
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France
185 Activités
198 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de la vessie urinaire Tumeurs de la prostate Carcinome transitionnel Métastase tumorale Adénocarcinome Tumeurs du poumon Carcinome pulmonaire non à petites cellules Néphrocarcinome

Collaborateurs

Voir plus
Culine Stephane
Culine Stephane
Hôpital Saint-Louis, Paris, France
Flechon Aude
Flechon Aude
Centre Léon-Bérard, Lyon, France
Loriot Yohann
Loriot Yohann
Gustave-Roussy, Villejuif, France
Mourey Loic
Mourey Loic
Oncopole Toulouse, Toulouse, France

Industries

Voir plus
MSD
25 collaboration(s)
Dernière en 2023
A+A
24 collaboration(s)
Dernière en 2023
Astellas
20 collaboration(s)
Dernière en 2023
Pfizer
15 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
TROPHY U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Essai Clinique (Gilead)   20 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
EDEN: Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   23 janvier 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Annals of oncology : official journal of the European Society for Medical Oncology   18 janvier 2024
GETUGV04: A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer
Essai Clinique (Institut du Cancer de Montpellier)   05 décembre 2023
Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201.
Annals of oncology : official journal of the European Society for Medical Oncology   11 novembre 2023
2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023